ArticleJournal of personalized medicine2023
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS).
Open access · goldAbstract read
In one paragraph
Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab.Rheumatology (Oxford, England) · 2025Trial
- Trial
- Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort.Lupus science & medicine · 2026Article
- Belimumab in Systemic Lupus Erythematosus: From B-Cell Biology to Disease Modification.Journal of clinical medicine · 2026Review
- Effect of Belimumab on the Cutaneous Manifestations of Patients With Lupus Erythematosus.International journal of dermatology · 2026Article
- What's New in Cutaneous Lupus Erythematosus: Guidelines, Biologics, and Beyond.The Journal of clinical and aesthetic dermatology · 2026Review
- Factors influencing the choice of non-biologic versus biologic immunosuppressive therapy in systemic lupus erythematosus.Scientific reports · 2025Article
- 2025 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus.Rheumatology and immunology research · 2025Article
- Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials.Rheumatology (Oxford, England) · 2025Article
- Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years.Arthritis research & therapy · 2025Article
- Efficacy and safety of belimumab versus rituximab for refractory immune thrombocytopenia in patients with connective tissue disease.Lupus science & medicine · 2025Article
- Efficacy of Belimumab on Different Joint and Skin Manifestations of Systemic Lupus Erythematosus: Real-Life Data from a New Multicentric, Nationwide Italian Cohort (BeRLiSS-JS 2.0).Biologics : targets & therapy · 2025Article
- Efficacy and safety of telitacicept in systemic lupus erythematosus with lupus nephritis and nephrotic syndrome: a 12-month retrospective cohort study.Frontiers in pharmacology · 2025Article
- [Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Belimumab 10 years later: how drug positioning has changed.Immunologic research · 2024Article
- When is the right time to change therapy? An observational study of the time to response to immunosuppressive drugs in systemic lupus erythematosus.Lupus science & medicine · 2024Observational
- Evaluating the real-world effectiveness of belimumab in patients with SLE using SLE-related laboratory values and rheumatoid arthritis-derived disease activity measures: RAPID3, swollen joint count and tender joint count.Lupus science & medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
54 authors at 20 institutions in 1 country.
Margherita ZenRheumatology Unit, Department of Medicine-DIMED, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.ORCID 0000-0003-0835-1406
Mariele GattoRheumatology Unit, Department of Medicine-DIMED, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.ORCID 0000-0003-4012-1248
Roberto DepascaleRheumatology Unit, Department of Medicine-DIMED, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.
Francesca RegolaASST Spedali Civili di Brescia, Department of Clinical and Experimental Sciences, Rheumatology and Clinical Immunology, 25123 Brescia, Italy.ORCID 0000-0001-6560-1112
Micaela FrediASST Spedali Civili di Brescia, Department of Clinical and Experimental Sciences, Rheumatology and Clinical Immunology, 25123 Brescia, Italy.
Laura AndreoliASST Spedali Civili di Brescia, Department of Clinical and Experimental Sciences, Rheumatology and Clinical Immunology, 25123 Brescia, Italy.ORCID 0000-0002-9107-3218
Franco FranceschiniASST Spedali Civili di Brescia, Department of Clinical and Experimental Sciences, Rheumatology and Clinical Immunology, 25123 Brescia, Italy.ORCID 0000-0003-3678-6124
Maria Letizia UrbanDepartment of Experimental and Clinical Medicine, University of Florence, 50139 Firenze, Italy.
Giacomo EmmiDepartment of Experimental and Clinical Medicine, University of Florence, 50139 Firenze, Italy.
Fulvia CeccarelliDipartimento Universitario di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari (SCIAC) 'Sapienza' University, 00185 Rome, Italy.
Fabrizio ContiDipartimento Universitario di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari (SCIAC) 'Sapienza' University, 00185 Rome, Italy.
Alessandra BortoluzziRheumatology Unit, Azienda Ospedaliero-Universitaria S. Anna-Ferrara, University of Ferrara, 44121 Ferrara, Italy.
Marcello GovoniRheumatology Unit, Azienda Ospedaliero-Universitaria S. Anna-Ferrara, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0003-0499-5773
Chiara TaniRheumatology, University of Pisa, 56124 Pisa, Italy.
Marta MoscaRheumatology, University of Pisa, 56124 Pisa, Italy.
Tania UbialiClinical Rheumatology Unit Milano, ASST Gaetano Pini, Department of Clinical Sciences and Community Health, Lombardia, 20129 Milan, Italy.ORCID 0000-0001-6790-5064
Maria GerosaClinical Rheumatology Unit Milano, ASST Gaetano Pini, Department of Clinical Sciences and Community Health, Lombardia, 20129 Milan, Italy.
Enrica P BozzoloUnit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, 20100 Milan, Italy.
Valentina CantiUnit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, 20100 Milan, Italy.
Paolo CardinalettiDipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, 60121 Ancona, Italy.
Armando GabrielliDipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, 60121 Ancona, Italy.
Giacomo TantiDivision of Rheumatology, Università Cattolica del Sacro Cuore Sede di Roma, 00168 Rome, Italy.
Elisa GremeseDivision of Rheumatology, Università Cattolica del Sacro Cuore Sede di Roma, 00168 Rome, Italy.
Ginevra De MarchiRheumatology Unit, University of Udine, Medical Area, 33100 Udine, Italy.ORCID 0000-0002-3087-8477
Salvatore De VitaRheumatology Unit, University of Udine, Medical Area, 33100 Udine, Italy.
Serena FasanoDeparment of Precision Medicine Napoli, Università degli Studi della Campania Luigi Vanvitelli, 81100 Caserta, Italy.ORCID 0000-0002-4718-4551
Francesco CicciaDeparment of Precision Medicine Napoli, Università degli Studi della Campania Luigi Vanvitelli, 81100 Caserta, Italy.ORCID 0000-0002-9352-1264
Giulia PazzolaAzienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Carlo SalvaraniAzienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Simone NegriniInternal Medicine Unit, Department of Internal Medicine, Università degli Studi di Genova, 16146 Genoa, Italy.ORCID 0000-0003-1267-4320
Andrea Di MatteoDeparment of Clinical and Experimental Sciences, Università Politecnica delle Marche, Rheumatology Clinic, 60131 Ancona, Italy.
Rossella De AngelisDeparment of Clinical and Experimental Sciences, Università Politecnica delle Marche, Rheumatology Clinic, 60131 Ancona, Italy.ORCID 0000-0001-5169-3511
Giovanni OrsoliniUnit of Rheumatology, University of di Verona, 37134 Verona, Italy.
Maurizio RossiniUnit of Rheumatology, University of di Verona, 37134 Verona, Italy.ORCID 0000-0001-9692-2293
Paola FaggioliASST OVEST Milanese Presidio di Legnano, 20025 Legnano, Italy.
Antonella LariaASST OVEST Milanese Presidio di Magenta, 20013 Magenta, Italy.
Matteo PigaRheumatology Unit, AOU University Clinic, University of Cagliari, 09124 Cagliari, Italy.ORCID 0000-0002-1126-8315
Alberto CauliRheumatology Unit, AOU University Clinic, University of Cagliari, 09124 Cagliari, Italy.
Salvatore ScarpatoRheumatology, Ospedale M. Scarlato, Scafati, 84018 Salerno, Italy.
Francesca Wanda RossiDipartimento di Scienze Mediche, Traslazionali e Centro di Ricerca Immunologia Base e Clinica (CISI), University of Napoli Federico II, 80131 Napoli, Italy.
Amato De PaulisDipartimento di Scienze Mediche, Traslazionali e Centro di Ricerca Immunologia Base e Clinica (CISI), University of Napoli Federico II, 80131 Napoli, Italy.
Enrico BrunettaIRCCS Humanitas Research Hospital, Milan, Italy, 20089 Milan, Italy.
Angela CeribelliDepartment of Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, 20089 Milan, Italy.
Carlo SelmiDepartment of Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, 20089 Milan, Italy.ORCID 0000-0002-0323-0376
Marcella PreteUnit of Internal Medicine, Department of Biomedical Sciences and Human Oncology, University of Bari, 70125 Bari, Italy.
Vito RacanelliUnit of Internal Medicine, Department of Biomedical Sciences and Human Oncology, University of Bari, 70125 Bari, Italy.ORCID 0000-0002-8639-1940
Angelo VaccaUnit of Internal Medicine, Department of Biomedical Sciences and Human Oncology, University of Bari, 70125 Bari, Italy.ORCID 0000-0002-4567-8216
Elena BartoloniRheumatology Unit, Department of Medicine, University of Perugia, 06121 Perugia, Italy.ORCID 0000-0003-4776-2136
Roberto GerliRheumatology Unit, Department of Medicine, University of Perugia, 06121 Perugia, Italy.
Elisabetta ZanattaRheumatology Unit, Department of Medicine-DIMED, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.
Maddalena LarosaRheumatology Unit, Department of Medicine-DIMED, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.
Francesca SacconRheumatology Unit, Department of Medicine-DIMED, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.
Andrea DoriaRheumatology Unit, Department of Medicine-DIMED, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.ORCID 0000-0003-0548-4983
Luca IaccarinoRheumatology Unit, Department of Medicine-DIMED, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy.
University of Padua · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITMarche Polytechnic University · ITUniversity of Bari Aldo Moro · ITHumanitas University · ITIRCCS Ospedale San Raffaele · ITIstituto Ortopedico Gaetano Pini · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Cagliari · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Ferrara · ITUniversity of Florence · ITUniversity of Naples Federico II · ITUniversity of Perugia · ITUniversity of Pisa · ITUniversity of Udine · ITUniversity of Verona · ITAzienda Ospedaliera Ospedale Civile di Legnano · ITAzienda Sanitaria Unità Locale di Reggio Emilia · ITAziende Socio Sanitarie Territoriale Ovest Milanese
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the efficacy of belimumab in joint and skin manifestations in a nationwide cohort of patients with SLE.
methodsAll patients with skin and joint involvement enrolled in the BeRLiSS cohort were considered. Belimumab (intravenous, 10 mg/kg) effectiveness in joint and skin manifestations was assessed by DAS28 and CLASI, respectively. Attainment and predictors of DAS28 remission (<2.6) and LDA (≥2.6, ≤3.2), CLASI = 0, 1, and improvement in DAS28 and CLASI indices ≥20%, ≥50%, and ≥70% were evaluated at 6, 12, 24, and 36 months.
resultsDAS28 < 2.6 was achieved by 46%, 57%, and 71% of patients at 6, 12, and 24 months, respectively. CLASI = 0 was achieved by 36%, 48%, and 62% of patients at 6, 12, and 24 months, respectively. Belimumab showed a glucocorticoid-sparing effect, being glucocorticoid-free at 8.5%, 15.4%, 25.6%, and 31.6% of patients at 6, 12, 24, and 36 months, respectively. Patients achieving DAS-LDA and CLASI-50 at 6 months had a higher probability of remission at 12 months compared with those who did not (
conclusionsBelimumab led to clinical improvement in a significant proportion of patients with joint or skin involvement in a real-life setting and was associated with a glucocorticoid-sparing effect. A significant proportion of patients with a partial response at 6 months achieved remission later on during follow-up.
Indexed as
belimumabCutaneous LE Area and Severity Index (CLASI)disease activity score (DAS)-28low disease activityremissionsystemic lupus erythematosus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.